{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:10:43Z","timestamp":1784005843164,"version":"3.55.0"},"reference-count":110,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,18]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In thyroid cancer with marked laryngotracheal invasion, life-threatening airway stenosis necessitates urgent procedures such as extensive curative surgery, tracheostomy, stenting, or laser bronchoscopy. These interventions are invasive and may significantly compromise quality of life. In anaplastic thyroid cancer (ATC), the delay during genetic testing turnaround time before initiating targeted therapy poses an additional therapeutic challenge. This study aimed to assess lenvatinib (LEN) as an initial and bridging treatment to rapidly alleviate airway stenosis and avoid emergency invasive interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 14 patients with remarkable laryngotracheal invasion among 69 thyroid cancer patients treated with multikinase inhibitor(s). All 14 patients received LEN as first-line or post-paclitaxel treatment. Response was assessed by CT imaging per RECIST 1.1, with particular attention to changes in tumor size and airway diameter. Symptom improvement and adverse events, such as fistula formation, were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 14 patients, 13 showed tumor reduction and airway improvement on initial CT post-LEN induction. Median response rate was 28.4%, with airway diameter improving by 15.9% on the initial CT. Airway symptoms resolved in a median of 3 days. One patient developed a tumor-tracheal fistula, managed with LEN dose adjustment. LEN was also successfully used as a bridging therapy before BRAF-targeted treatment in ATC cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initial LEN therapy rapidly alleviates airway stenosis in advanced thyroid cancer with laryngotracheal invasion, offering a non-invasive alternative to emergency procedures under careful monitoring for fistula formation. LEN is especially valuable as a bridging therapy during the genetic testing period in ATC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0212","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T16:24:32Z","timestamp":1758212672000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":1,"title":["Lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-6278","authenticated-orcid":true,"given":"Hiroshi","family":"Katoh","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Hospital, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Hospital, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Hospital, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Tokito","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Hospital, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Hospital, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Sangai","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Hospital, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Am J Surg","first-page":"454","article-title":"Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis","volume":"200","author":"Morris LG","year":"2010","unstructured":"Morris LG\n & \nMyssiorek D\n\n. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg 2010 200 454\u2013461. (https:\/\/doi.org\/10.1016\/j.amjsurg.2009.11.008)"},{"key":"bib2","series-title":"Am J Hosp Palliat Care","first-page":"19","article-title":"Outcomes of airway stents in the palliative care of patients with cancer","volume":"38","author":"Catarata MJP","year":"2021","unstructured":"Catarata MJP\n, \nSaleiro S\n & \nAraujo VS\n\n. Outcomes of airway stents in the palliative care of patients with cancer. Am J Hosp Palliat Care 2021 38 19\u201324. (https:\/\/doi.org\/10.1177\/1049909120926466)"},{"key":"bib3","series-title":"Case Rep Pulmonol","article-title":"Bronchoscopy laser and silicone Y-stents as emergency airway management in central airway stenosis due to secondary thyroid carcinoma: a case report","volume":"2022","author":"Elhidsi M","year":"2022","unstructured":"Elhidsi M\n, \nSoehardiman D\n, \nWibawanto A\n, et al.\n Bronchoscopy laser and silicone Y-stents as emergency airway management in central airway stenosis due to secondary thyroid carcinoma: a case report. Case Rep Pulmonol 2022 2022 6338073. (https:\/\/doi.org\/10.1155\/2022\/6338073)"},{"key":"bib4","series-title":"Thyroid","first-page":"1","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen BR","year":"2016","unstructured":"Haugen BR\n, \nAlexander EK\n, \nBible KC\n, et al.\n 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016 26 1\u2013133. (https:\/\/doi.org\/10.1089\/thy.2015.0020)"},{"key":"bib5","series-title":"Chest","first-page":"283","article-title":"Management of central airway obstruction: an American college of chest physicians clinical practice guideline","volume":"167","author":"Mahmood K","year":"2025","unstructured":"Mahmood K\n, \nFrazer-Green L\n, \nGonzalez AV\n, et al.\n Management of central airway obstruction: an American college of chest physicians clinical practice guideline. Chest 2025 167 283\u2013295. (https:\/\/doi.org\/10.1016\/j.chest.2024.06.3804)"},{"key":"bib6","series-title":"PLoS One","article-title":"Indications of airway stenting for severe central airway obstruction due to advanced cancer","volume":"12","author":"Nagano H","year":"2017","unstructured":"Nagano H\n, \nKishaba T\n, \nNei Y\n, et al.\n Indications of airway stenting for severe central airway obstruction due to advanced cancer. PLoS One 2017 12 e0179795. (https:\/\/doi.org\/10.1371\/journal.pone.0179795)"},{"key":"bib7","series-title":"Gland Surg","first-page":"574","article-title":"Complications from tracheal resection for thyroid carcinoma","volume":"6","author":"Rotolo N","year":"2017","unstructured":"Rotolo N\n, \nCattoni M\n & \nImperatori A\n\n. Complications from tracheal resection for thyroid carcinoma. Gland Surg 2017 6 574\u2013578. (https:\/\/doi.org\/10.21037\/gs.2017.08.05)"},{"key":"bib8","series-title":"Clin Otolaryngol","first-page":"414","article-title":"A systematic review of endotracheal stenting in patients with locally advanced thyroid cancer","volume":"47","author":"Schuster-Bruce J","year":"2022","unstructured":"Schuster-Bruce J\n, \nSargent P\n, \nMadden B\n, et al.\n A systematic review of endotracheal stenting in patients with locally advanced thyroid cancer. Clin Otolaryngol 2022 47 414\u2013423. (https:\/\/doi.org\/10.1111\/coa.13923)"},{"key":"bib9","series-title":"G Chir","first-page":"390","article-title":"Management of anaplastic thyroid carcinoma spread over the trachea with mediastinal extension","volume":"31","author":"Falco CE","year":"2010","unstructured":"Falco CE\n, \nGrande AM\n, \nNicolardi S\n, et al.\n Management of anaplastic thyroid carcinoma spread over the trachea with mediastinal extension. G Chir 2010 31 390\u2013393."},{"key":"bib10","series-title":"Head Neck","first-page":"85","article-title":"Management of the compromised airway and role of tracheotomy in anaplastic thyroid carcinoma","volume":"38","author":"Mani N","year":"2016","unstructured":"Mani N\n, \nMcNamara K\n, \nLowe N\n, et al.\n Management of the compromised airway and role of tracheotomy in anaplastic thyroid carcinoma. Head Neck 2016 38 85\u201388. (https:\/\/doi.org\/10.1002\/hed.23857)"},{"key":"bib11","series-title":"Curr Opin Otolaryngol Head Neck Surg","first-page":"74","article-title":"Airway management, symptom relief and best supportive care in anaplastic thyroid cancer","volume":"28","author":"Moyer KF","year":"2020","unstructured":"Moyer KF\n, \nMarcadis AR\n & \nShaha AR\n\n. Airway management, symptom relief and best supportive care in anaplastic thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 2020 28 74\u201378. (https:\/\/doi.org\/10.1097\/moo.0000000000000619)"},{"key":"bib12","series-title":"Eur Arch Otorhinolaryngol","first-page":"2579","article-title":"Airway issues in anaplastic thyroid carcinoma","volume":"270","author":"Shaha AR","year":"2013","unstructured":"Shaha AR\n, \nFerlito A\n, \nOwen RP\n, et al.\n Airway issues in anaplastic thyroid carcinoma. Eur Arch Otorhinolaryngol 2013 270 2579\u20132583. (https:\/\/doi.org\/10.1007\/s00405-013-2556-3)"},{"key":"bib13","series-title":"World J Oncol","first-page":"262","article-title":"The role of tracheostomy in Anaplastic thyroid carcinoma","volume":"6","author":"Xu J","year":"2015","unstructured":"Xu J\n, \nLiao Z\n, \nLi JJ\n, et al.\n The role of tracheostomy in Anaplastic thyroid carcinoma. World J Oncol 2015 6 262\u2013264. (https:\/\/doi.org\/10.14740\/wjon899w)"},{"key":"bib14","series-title":"Respiration","first-page":"441","article-title":"Experience with transcordal silicone stents in adult laryngotracheal stenosis: a bicentric retrospective study","volume":"95","author":"Bourinet V","year":"2018","unstructured":"Bourinet V\n, \nRaguin T\n, \nFortin M\n, et al.\n Experience with transcordal silicone stents in adult laryngotracheal stenosis: a bicentric retrospective study. Respiration 2018 95 441\u2013448. (https:\/\/doi.org\/10.1159\/000487242)"},{"key":"bib15","series-title":"BMC Pulm Med","first-page":"383","article-title":"Subcutaneous fixation model for complex stenting of recurrent laryngotracheal stenosis","volume":"24","author":"Meyer S","year":"2024","unstructured":"Meyer S\n, \nd\u2019Od\u00e9mont JP\n, \nPutz L\n, et al.\n Subcutaneous fixation model for complex stenting of recurrent laryngotracheal stenosis. BMC Pulm Med 2024 24 383. (https:\/\/doi.org\/10.1186\/s12890-024-03197-1)"},{"key":"bib16","series-title":"Future Oncol","first-page":"13","article-title":"Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma","volume":"15","author":"Gay S","year":"2019","unstructured":"Gay S\n, \nMonti E\n, \nTrambaiolo Antonelli C\n, et al.\n Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Future Oncol 2019 15 13\u201319. (https:\/\/doi.org\/10.2217\/fon-2019-0099)"},{"key":"bib17","series-title":"Case Rep Endocrinol","first-page":"6438352","article-title":"A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy","volume":"2020","author":"Iwasaki H","year":"2020","unstructured":"Iwasaki H\n, \nToda S\n, \nIto H\n, et al.\n A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy. Case Rep Endocrinol 2020 2020 6438352. (https:\/\/doi.org\/10.1155\/2020\/6438352)"},{"key":"bib18","series-title":"Int J Endocr Oncol","first-page":"IJE33","article-title":"Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels","volume":"7","author":"Katoh H","year":"2021","unstructured":"Katoh H\n, \nKajita S\n, \nYokota M\n, et al.\n Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels. Int J Endocr Oncol 2021 7 IJE33. (https:\/\/doi.org\/10.2217\/ije-2020-0014)"},{"key":"bib19","series-title":"Front Endocrinol","first-page":"712","article-title":"Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma","volume":"10","author":"Nava CF","year":"2019","unstructured":"Nava CF\n, \nScheffel RS\n, \nCristo AP\n, et al.\n Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma. Front Endocrinol 2019 10 712. (https:\/\/doi.org\/10.3389\/fendo.2019.00712)"},{"key":"bib20","series-title":"Eur Thyroid J","first-page":"102","article-title":"Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report","volume":"8","author":"Stewart KE","year":"2019","unstructured":"Stewart KE\n, \nStrachan MWJ\n, \nSrinivasan D\n, et al.\n Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur Thyroid J 2019 8 102\u2013107. (https:\/\/doi.org\/10.1159\/000494880)"},{"key":"bib21","series-title":"Surg Case Rep","first-page":"38","article-title":"Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report","volume":"9","author":"Yamazaki H","year":"2023","unstructured":"Yamazaki H\n, \nMasudo K\n, \nKanada S\n, et al.\n Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report. Surg Case Rep 2023 9 38. (https:\/\/doi.org\/10.1186\/s40792-023-01619-6)"},{"key":"bib22","series-title":"World J Surg Oncol","first-page":"84","article-title":"Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review","volume":"17","author":"Sheu NW","year":"2019","unstructured":"Sheu NW\n, \nJiang HJ\n, \nWu CW\n, et al.\n Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review. World J Surg Oncol 2019 17 84. (https:\/\/doi.org\/10.1186\/s12957-019-1626-4)"},{"key":"bib23","series-title":"Cancer Rep","article-title":"Neoadjuvant lenvatinib for inoperable thyroid cancer: a case report and literature review","volume":"5","author":"Alshehri K","year":"2022","unstructured":"Alshehri K\n, \nAlqurashi Y\n, \nMerdad M\n, et al.\n Neoadjuvant lenvatinib for inoperable thyroid cancer: a case report and literature review. Cancer Rep 2022 5 e1466. (https:\/\/doi.org\/10.1002\/cnr2.1466)"},{"key":"bib24","series-title":"Thyroid","first-page":"949","article-title":"Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary Latin American experience","volume":"34","author":"Pitoia F","year":"2024","unstructured":"Pitoia F\n, \nAbelleira E\n, \nRoman-Gonzalez A\n, et al.\n Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary Latin American experience. Thyroid 2024 34 949\u2013952. (https:\/\/doi.org\/10.1089\/thy.2024.0090)"},{"key":"bib25","series-title":"Cureus","article-title":"Advanced unresectable differentiated thyroid cancer with anaplastic transformation: a case report and review of the literature","volume":"16","author":"Alzahrani J","year":"2024","unstructured":"Alzahrani J\n, \nRadi S\n, \nAljabri A\n, et al.\n Advanced unresectable differentiated thyroid cancer with anaplastic transformation: a case report and review of the literature. Cureus 2024 16 e73956. (https:\/\/doi.org\/10.7759\/cureus.73956)"},{"key":"bib26","series-title":"Front Endocrinol","article-title":"Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report","volume":"15","author":"Barbaro D","year":"2024","unstructured":"Barbaro D\n, \nForleo R\n, \nProfilo MA\n, et al.\n Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report. Front Endocrinol 2024 15 1389294. (https:\/\/doi.org\/10.3389\/fendo.2024.1389294)"},{"key":"bib27","series-title":"Surgery","article-title":"Neoadjuvant systemic therapy for inoperable differentiated thyroid cancers: impact on tumor resectability","volume":"177","author":"Dickerson K","year":"2025","unstructured":"Dickerson K\n, \nMilas M\n, \nMetzger R\n, et al.\n Neoadjuvant systemic therapy for inoperable differentiated thyroid cancers: impact on tumor resectability. Surgery 2025 177 108836. (https:\/\/doi.org\/10.1016\/j.surg.2024.08.046)"},{"key":"bib28","series-title":"Ann Oncol","first-page":"406","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah V","year":"2022","unstructured":"Subbiah V\n, \nKreitman RJ\n, \nWainberg ZA\n, et al.\n Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022 33 406\u2013415. (https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014)"},{"key":"bib29","series-title":"Thyroid","first-page":"536","article-title":"Inclusion of the number of metastatic lymph nodes in the staging system for medullary thyroid cancer: validating a modified American Joint Committee on cancer tumor-node-metastasis staging system","volume":"32","author":"Wang Z","year":"2022","unstructured":"Wang Z\n, \nTang C\n, \nWang Y\n, et al.\n Inclusion of the number of metastatic lymph nodes in the staging system for medullary thyroid cancer: validating a modified American Joint Committee on cancer tumor-node-metastasis staging system. Thyroid 2022 32 536\u2013543. (https:\/\/doi.org\/10.1089\/thy.2021.0571)"},{"key":"bib30","series-title":"Thorac Cancer","article-title":"Suitability of frozen pleural fluid pellets for next-generation sequencing-based driver gene testing in non-small cell lung cancer","volume":"16","author":"Nakashima K","year":"2025","unstructured":"Nakashima K\n, \nOtsubo K\n, \nTsuchiya-Kawano Y\n, et al.\n Suitability of frozen pleural fluid pellets for next-generation sequencing-based driver gene testing in non-small cell lung cancer. Thorac Cancer 2025 16 e70107. (https:\/\/doi.org\/10.1111\/1759-7714.70107)"},{"key":"bib31","series-title":"Curr Oncol","first-page":"e595","article-title":"Reconsidering the turnaround times for BRAF V600 mutation analysis in non-small-cell lung cancer: a molecular diagnosis in one day is achievable for rapid treatment choices","volume":"26","author":"Uguen A","year":"2019","unstructured":"Uguen A\n\n. Reconsidering the turnaround times for BRAF V600 mutation analysis in non-small-cell lung cancer: a molecular diagnosis in one day is achievable for rapid treatment choices. Curr Oncol 2019 26 e595\u2013e596. (https:\/\/doi.org\/10.3747\/co.26.4779)"},{"key":"bib32","series-title":"Eur J Cancer","first-page":"210","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama T","year":"2022","unstructured":"Higashiyama T\n, \nSugino K\n, \nHara H\n, et al.\n Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer 2022 173 210\u2013218. (https:\/\/doi.org\/10.1016\/j.ejca.2022.06.044)"},{"key":"bib33","series-title":"Thyroid","first-page":"1076","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks C","year":"2021","unstructured":"Dierks C\n, \nSeufert J\n, \nAumann K\n, et al.\n Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 2021 31 1076\u20131085. (https:\/\/doi.org\/10.1089\/thy.2020.0322)"},{"key":"bib34","series-title":"Clin Cancer Res","first-page":"3757","article-title":"Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers","volume":"30","author":"French JD","year":"2024","unstructured":"French JD\n, \nHaugen BR\n, \nWorden FP\n, et al.\n Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. Clin Cancer Res 2024 30 3757\u20133767. (https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-3417)"},{"key":"bib35","series-title":"Curr Oncol","first-page":"5401","article-title":"Combination of lenvatinib and pembrolizumab as salvage treatment for paucicellular variant of anaplastic thyroid cancer: a case report","volume":"28","author":"Luongo C","year":"2021","unstructured":"Luongo C\n, \nPorcelli T\n, \nSessa F\n, et al.\n Combination of lenvatinib and pembrolizumab as salvage treatment for paucicellular variant of anaplastic thyroid cancer: a case report. Curr Oncol 2021 28 5401\u20135407. (https:\/\/doi.org\/10.3390\/curroncol28060450)"},{"key":"bib36","series-title":"BMC Endocr Disord","first-page":"25","article-title":"First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study","volume":"24","author":"Soll D","year":"2024","unstructured":"Soll D\n, \nBischoff P\n, \nFrisch A\n, et al.\n First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. BMC Endocr Disord 2024 24 25. (https:\/\/doi.org\/10.1186\/s12902-024-01555-y)"},{"key":"bib37","series-title":"Endocr J","first-page":"545","article-title":"The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery","volume":"72","author":"Sugitani I","year":"2025","unstructured":"Sugitani I\n, \nKiyota N\n, \nIto Y\n, et al.\n The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery. Endocr J 2025 72 545\u2013635. (https:\/\/doi.org\/10.1507\/endocrj.ej24-0644)"},{"key":"bib38","series-title":"J Natl Cancer Inst","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse P","year":"2000","unstructured":"Therasse P\n, \nArbuck SG\n, \nEisenhauer EA\n, et al.\n New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 205\u2013216. (https:\/\/doi.org\/10.1093\/jnci\/92.3.205)"},{"key":"bib39","series-title":"Thyroid","first-page":"918","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins DP","year":"2014","unstructured":"Blevins DP\n, \nDadu R\n, \nHu M\n, et al.\n Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 2014 24 918\u2013922. (https:\/\/doi.org\/10.1089\/thy.2012.0598)"},{"key":"bib40","series-title":"Eur Thyroid J","first-page":"399","article-title":"Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer","volume":"10","author":"Valerio L","year":"2021","unstructured":"Valerio L\n, \nGiani C\n, \nAgate L\n, et al.\n Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer. Eur Thyroid J 2021 10 399\u2013407. (https:\/\/doi.org\/10.1159\/000514182)"},{"key":"bib41","series-title":"N Engl J Med","first-page":"621","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger M","year":"2015","unstructured":"Schlumberger M\n, \nTahara M\n, \nWirth LJ\n, et al.\n Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015 372 621\u2013630. (https:\/\/doi.org\/10.1056\/nejmoa1406470)"},{"key":"bib42","series-title":"J Clin Oncol","first-page":"2359","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth LJ","year":"2021","unstructured":"Wirth LJ\n, \nBrose MS\n, \nSherman EJ\n, et al.\n Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol 2021 39 2359\u20132366. (https:\/\/doi.org\/10.1200\/jco.20.03093)"},{"key":"bib43","series-title":"Oncol Lett","first-page":"416","article-title":"Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer","volume":"26","author":"Iwasaki H","year":"2023","unstructured":"Iwasaki H\n, \nToda S\n, \nTakahashi A\n, et al.\n Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer. Oncol Lett 2023 26 416. (https:\/\/doi.org\/10.3892\/ol.2023.14002)"},{"key":"bib44","series-title":"Endocrine","first-page":"208","article-title":"Lenvatinib for unresectable anaplastic thyroid cancer: real-world experiences in multi-institutional study","volume":"90","author":"Mikoshiba T","year":"2025","unstructured":"Mikoshiba T\n, \nSekimizu M\n, \nKono T\n, et al.\n Lenvatinib for unresectable anaplastic thyroid cancer: real-world experiences in multi-institutional study. Endocrine 2025 90 208\u2013214. (https:\/\/doi.org\/10.1007\/s12020-025-04333-5)"},{"key":"bib45","series-title":"J Clin Endocrinol Metab","first-page":"4103","article-title":"Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer","volume":"101","author":"Robinson B","year":"2016","unstructured":"Robinson B\n, \nSchlumberger M\n, \nWirth LJ\n, et al.\n Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 2016 101 4103\u20134109. (https:\/\/doi.org\/10.1210\/jc.2015-3989)"},{"key":"bib46","series-title":"Anticancer Res","first-page":"3871","article-title":"Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer","volume":"39","author":"Staub Y","year":"2019","unstructured":"Staub Y\n, \nNishiyama A\n, \nSuga Y\n, et al.\n Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer. Anticancer Res 2019 39 3871\u20133878. (https:\/\/doi.org\/10.21873\/anticanres.13537)"},{"key":"bib47","series-title":"Cancer Chemother Pharmacol","first-page":"971","article-title":"Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer","volume":"82","author":"Hayato S","year":"2018","unstructured":"Hayato S\n, \nShumaker R\n, \nFerry J\n, et al.\n Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer Chemother Pharmacol 2018 82 971\u2013978. (https:\/\/doi.org\/10.1007\/s00280-018-3687-4)"},{"key":"bib48","series-title":"Front Oncol","article-title":"Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study","volume":"13","author":"Matsuyama C","year":"2023","unstructured":"Matsuyama C\n, \nEnokida T\n, \nUeda Y\n, et al.\n Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 2023 13 1139659. (https:\/\/doi.org\/10.3389\/fonc.2023.1139659)"},{"key":"bib49","series-title":"Thyroid","first-page":"566","article-title":"A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer","volume":"34","author":"Tahara M","year":"2024","unstructured":"Tahara M\n, \nTakami H\n, \nIto Y\n, et al.\n A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid 2024 34 566\u2013574. (https:\/\/doi.org\/10.1089\/thy.2023.0553)"},{"key":"bib50","series-title":"Front Oncol","article-title":"Core needle biopsy can early and precisely identify large thyroid masses","volume":"12","author":"Matrone A","year":"2022","unstructured":"Matrone A\n, \nDe Napoli L\n, \nTorregrossa L\n, et al.\n Core needle biopsy can early and precisely identify large thyroid masses. Front Oncol 2022 12 854755. (https:\/\/doi.org\/10.3389\/fonc.2022.854755)"},{"key":"bib51","series-title":"Front Endocrinol","article-title":"Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: a systematic review and meta-analysis","volume":"13","author":"Vander Poorten V","year":"2022","unstructured":"Vander Poorten V\n, \nGoedseels N\n, \nTriantafyllou A\n, et al.\n Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: a systematic review and meta-analysis. Front Endocrinol 2022 13 971249. (https:\/\/doi.org\/10.3389\/fendo.2022.971249)"},{"key":"bib52","series-title":"Int J Clin Oncol","first-page":"1143","article-title":"Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer","volume":"30","author":"Onaga R","year":"2025","unstructured":"Onaga R\n, \nEnokida T\n, \nSakashita S\n, et al.\n Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer. Int J Clin Oncol 2025 30 1143\u20131151. (https:\/\/doi.org\/10.1007\/s10147-025-02760-y)"},{"key":"bib53","series-title":"Acta Neuropathol","first-page":"11","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper D","year":"2011","unstructured":"Capper D\n, \nPreusser M\n, \nHabel A\n, et al.\n Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011 122 11\u201319. (https:\/\/doi.org\/10.1007\/s00401-011-0841-z)"},{"key":"bib54","series-title":"Ann Oncol","first-page":"742","article-title":"Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients","volume":"24","author":"Ilie M","year":"2013","unstructured":"Ilie M\n, \nLong E\n, \nHofman V\n, et al.\n Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013 24 742\u2013748. (https:\/\/doi.org\/10.1093\/annonc\/mds534)"},{"key":"bib55","series-title":"Head Neck Pathol","first-page":"1067","article-title":"Comparison of molecular methods and BRAF immunohistochemistry (VE1 clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis","volume":"14","author":"Parker KG","year":"2020","unstructured":"Parker KG\n, \nWhite MG\n & \nCipriani NA\n\n. Comparison of molecular methods and BRAF immunohistochemistry (VE1 clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis. Head Neck Pathol 2020 14 1067\u20131079. (https:\/\/doi.org\/10.1007\/s12105-020-01166-8)"},{"key":"bib1","series-title":"Am J Surg","first-page":"454","article-title":"Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis","volume":"200","author":"Morris LG","year":"2010","unstructured":"Morris LG\n & \nMyssiorek D\n\n. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg 2010 200 454\u2013461. (https:\/\/doi.org\/10.1016\/j.amjsurg.2009.11.008)"},{"key":"bib2","series-title":"Am J Hosp Palliat Care","first-page":"19","article-title":"Outcomes of airway stents in the palliative care of patients with cancer","volume":"38","author":"Catarata MJP","year":"2021","unstructured":"Catarata MJP\n, \nSaleiro S\n & \nAraujo VS\n\n. Outcomes of airway stents in the palliative care of patients with cancer. Am J Hosp Palliat Care 2021 38 19\u201324. (https:\/\/doi.org\/10.1177\/1049909120926466)"},{"key":"bib3","series-title":"Case Rep Pulmonol","article-title":"Bronchoscopy laser and silicone Y-stents as emergency airway management in central airway stenosis due to secondary thyroid carcinoma: a case report","volume":"2022","author":"Elhidsi M","year":"2022","unstructured":"Elhidsi M\n, \nSoehardiman D\n, \nWibawanto A\n, et al.\n Bronchoscopy laser and silicone Y-stents as emergency airway management in central airway stenosis due to secondary thyroid carcinoma: a case report. Case Rep Pulmonol 2022 2022 6338073. (https:\/\/doi.org\/10.1155\/2022\/6338073)"},{"key":"bib4","series-title":"Thyroid","first-page":"1","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen BR","year":"2016","unstructured":"Haugen BR\n, \nAlexander EK\n, \nBible KC\n, et al.\n 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016 26 1\u2013133. (https:\/\/doi.org\/10.1089\/thy.2015.0020)"},{"key":"bib5","series-title":"Chest","first-page":"283","article-title":"Management of central airway obstruction: an American college of chest physicians clinical practice guideline","volume":"167","author":"Mahmood K","year":"2025","unstructured":"Mahmood K\n, \nFrazer-Green L\n, \nGonzalez AV\n, et al.\n Management of central airway obstruction: an American college of chest physicians clinical practice guideline. Chest 2025 167 283\u2013295. (https:\/\/doi.org\/10.1016\/j.chest.2024.06.3804)"},{"key":"bib6","series-title":"PLoS One","article-title":"Indications of airway stenting for severe central airway obstruction due to advanced cancer","volume":"12","author":"Nagano H","year":"2017","unstructured":"Nagano H\n, \nKishaba T\n, \nNei Y\n, et al.\n Indications of airway stenting for severe central airway obstruction due to advanced cancer. PLoS One 2017 12 e0179795. (https:\/\/doi.org\/10.1371\/journal.pone.0179795)"},{"key":"bib7","series-title":"Gland Surg","first-page":"574","article-title":"Complications from tracheal resection for thyroid carcinoma","volume":"6","author":"Rotolo N","year":"2017","unstructured":"Rotolo N\n, \nCattoni M\n & \nImperatori A\n\n. Complications from tracheal resection for thyroid carcinoma. Gland Surg 2017 6 574\u2013578. (https:\/\/doi.org\/10.21037\/gs.2017.08.05)"},{"key":"bib8","series-title":"Clin Otolaryngol","first-page":"414","article-title":"A systematic review of endotracheal stenting in patients with locally advanced thyroid cancer","volume":"47","author":"Schuster-Bruce J","year":"2022","unstructured":"Schuster-Bruce J\n, \nSargent P\n, \nMadden B\n, et al.\n A systematic review of endotracheal stenting in patients with locally advanced thyroid cancer. Clin Otolaryngol 2022 47 414\u2013423. (https:\/\/doi.org\/10.1111\/coa.13923)"},{"key":"bib9","series-title":"G Chir","first-page":"390","article-title":"Management of anaplastic thyroid carcinoma spread over the trachea with mediastinal extension","volume":"31","author":"Falco CE","year":"2010","unstructured":"Falco CE\n, \nGrande AM\n, \nNicolardi S\n, et al.\n Management of anaplastic thyroid carcinoma spread over the trachea with mediastinal extension. G Chir 2010 31 390\u2013393."},{"key":"bib10","series-title":"Head Neck","first-page":"85","article-title":"Management of the compromised airway and role of tracheotomy in anaplastic thyroid carcinoma","volume":"38","author":"Mani N","year":"2016","unstructured":"Mani N\n, \nMcNamara K\n, \nLowe N\n, et al.\n Management of the compromised airway and role of tracheotomy in anaplastic thyroid carcinoma. Head Neck 2016 38 85\u201388. (https:\/\/doi.org\/10.1002\/hed.23857)"},{"key":"bib11","series-title":"Curr Opin Otolaryngol Head Neck Surg","first-page":"74","article-title":"Airway management, symptom relief and best supportive care in anaplastic thyroid cancer","volume":"28","author":"Moyer KF","year":"2020","unstructured":"Moyer KF\n, \nMarcadis AR\n & \nShaha AR\n\n. Airway management, symptom relief and best supportive care in anaplastic thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 2020 28 74\u201378. (https:\/\/doi.org\/10.1097\/moo.0000000000000619)"},{"key":"bib12","series-title":"Eur Arch Otorhinolaryngol","first-page":"2579","article-title":"Airway issues in anaplastic thyroid carcinoma","volume":"270","author":"Shaha AR","year":"2013","unstructured":"Shaha AR\n, \nFerlito A\n, \nOwen RP\n, et al.\n Airway issues in anaplastic thyroid carcinoma. Eur Arch Otorhinolaryngol 2013 270 2579\u20132583. (https:\/\/doi.org\/10.1007\/s00405-013-2556-3)"},{"key":"bib13","series-title":"World J Oncol","first-page":"262","article-title":"The role of tracheostomy in Anaplastic thyroid carcinoma","volume":"6","author":"Xu J","year":"2015","unstructured":"Xu J\n, \nLiao Z\n, \nLi JJ\n, et al.\n The role of tracheostomy in Anaplastic thyroid carcinoma. World J Oncol 2015 6 262\u2013264. (https:\/\/doi.org\/10.14740\/wjon899w)"},{"key":"bib14","series-title":"Respiration","first-page":"441","article-title":"Experience with transcordal silicone stents in adult laryngotracheal stenosis: a bicentric retrospective study","volume":"95","author":"Bourinet V","year":"2018","unstructured":"Bourinet V\n, \nRaguin T\n, \nFortin M\n, et al.\n Experience with transcordal silicone stents in adult laryngotracheal stenosis: a bicentric retrospective study. Respiration 2018 95 441\u2013448. (https:\/\/doi.org\/10.1159\/000487242)"},{"key":"bib15","series-title":"BMC Pulm Med","first-page":"383","article-title":"Subcutaneous fixation model for complex stenting of recurrent laryngotracheal stenosis","volume":"24","author":"Meyer S","year":"2024","unstructured":"Meyer S\n, \nd\u2019Od\u00e9mont JP\n, \nPutz L\n, et al.\n Subcutaneous fixation model for complex stenting of recurrent laryngotracheal stenosis. BMC Pulm Med 2024 24 383. (https:\/\/doi.org\/10.1186\/s12890-024-03197-1)"},{"key":"bib16","series-title":"Future Oncol","first-page":"13","article-title":"Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma","volume":"15","author":"Gay S","year":"2019","unstructured":"Gay S\n, \nMonti E\n, \nTrambaiolo Antonelli C\n, et al.\n Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Future Oncol 2019 15 13\u201319. (https:\/\/doi.org\/10.2217\/fon-2019-0099)"},{"key":"bib17","series-title":"Case Rep Endocrinol","first-page":"6438352","article-title":"A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy","volume":"2020","author":"Iwasaki H","year":"2020","unstructured":"Iwasaki H\n, \nToda S\n, \nIto H\n, et al.\n A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy. Case Rep Endocrinol 2020 2020 6438352. (https:\/\/doi.org\/10.1155\/2020\/6438352)"},{"key":"bib18","series-title":"Int J Endocr Oncol","first-page":"IJE33","article-title":"Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels","volume":"7","author":"Katoh H","year":"2021","unstructured":"Katoh H\n, \nKajita S\n, \nYokota M\n, et al.\n Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels. Int J Endocr Oncol 2021 7 IJE33. (https:\/\/doi.org\/10.2217\/ije-2020-0014)"},{"key":"bib19","series-title":"Front Endocrinol","first-page":"712","article-title":"Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma","volume":"10","author":"Nava CF","year":"2019","unstructured":"Nava CF\n, \nScheffel RS\n, \nCristo AP\n, et al.\n Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma. Front Endocrinol 2019 10 712. (https:\/\/doi.org\/10.3389\/fendo.2019.00712)"},{"key":"bib20","series-title":"Eur Thyroid J","first-page":"102","article-title":"Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report","volume":"8","author":"Stewart KE","year":"2019","unstructured":"Stewart KE\n, \nStrachan MWJ\n, \nSrinivasan D\n, et al.\n Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur Thyroid J 2019 8 102\u2013107. (https:\/\/doi.org\/10.1159\/000494880)"},{"key":"bib21","series-title":"Surg Case Rep","first-page":"38","article-title":"Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report","volume":"9","author":"Yamazaki H","year":"2023","unstructured":"Yamazaki H\n, \nMasudo K\n, \nKanada S\n, et al.\n Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report. Surg Case Rep 2023 9 38. (https:\/\/doi.org\/10.1186\/s40792-023-01619-6)"},{"key":"bib22","series-title":"World J Surg Oncol","first-page":"84","article-title":"Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review","volume":"17","author":"Sheu NW","year":"2019","unstructured":"Sheu NW\n, \nJiang HJ\n, \nWu CW\n, et al.\n Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review. World J Surg Oncol 2019 17 84. (https:\/\/doi.org\/10.1186\/s12957-019-1626-4)"},{"key":"bib23","series-title":"Cancer Rep","article-title":"Neoadjuvant lenvatinib for inoperable thyroid cancer: a case report and literature review","volume":"5","author":"Alshehri K","year":"2022","unstructured":"Alshehri K\n, \nAlqurashi Y\n, \nMerdad M\n, et al.\n Neoadjuvant lenvatinib for inoperable thyroid cancer: a case report and literature review. Cancer Rep 2022 5 e1466. (https:\/\/doi.org\/10.1002\/cnr2.1466)"},{"key":"bib24","series-title":"Thyroid","first-page":"949","article-title":"Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary Latin American experience","volume":"34","author":"Pitoia F","year":"2024","unstructured":"Pitoia F\n, \nAbelleira E\n, \nRoman-Gonzalez A\n, et al.\n Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary Latin American experience. Thyroid 2024 34 949\u2013952. (https:\/\/doi.org\/10.1089\/thy.2024.0090)"},{"key":"bib25","series-title":"Cureus","article-title":"Advanced unresectable differentiated thyroid cancer with anaplastic transformation: a case report and review of the literature","volume":"16","author":"Alzahrani J","year":"2024","unstructured":"Alzahrani J\n, \nRadi S\n, \nAljabri A\n, et al.\n Advanced unresectable differentiated thyroid cancer with anaplastic transformation: a case report and review of the literature. Cureus 2024 16 e73956. (https:\/\/doi.org\/10.7759\/cureus.73956)"},{"key":"bib26","series-title":"Front Endocrinol","article-title":"Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report","volume":"15","author":"Barbaro D","year":"2024","unstructured":"Barbaro D\n, \nForleo R\n, \nProfilo MA\n, et al.\n Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report. Front Endocrinol 2024 15 1389294. (https:\/\/doi.org\/10.3389\/fendo.2024.1389294)"},{"key":"bib27","series-title":"Surgery","article-title":"Neoadjuvant systemic therapy for inoperable differentiated thyroid cancers: impact on tumor resectability","volume":"177","author":"Dickerson K","year":"2025","unstructured":"Dickerson K\n, \nMilas M\n, \nMetzger R\n, et al.\n Neoadjuvant systemic therapy for inoperable differentiated thyroid cancers: impact on tumor resectability. Surgery 2025 177 108836. (https:\/\/doi.org\/10.1016\/j.surg.2024.08.046)"},{"key":"bib28","series-title":"Ann Oncol","first-page":"406","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah V","year":"2022","unstructured":"Subbiah V\n, \nKreitman RJ\n, \nWainberg ZA\n, et al.\n Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022 33 406\u2013415. (https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014)"},{"key":"bib29","series-title":"Thyroid","first-page":"536","article-title":"Inclusion of the number of metastatic lymph nodes in the staging system for medullary thyroid cancer: validating a modified American Joint Committee on cancer tumor-node-metastasis staging system","volume":"32","author":"Wang Z","year":"2022","unstructured":"Wang Z\n, \nTang C\n, \nWang Y\n, et al.\n Inclusion of the number of metastatic lymph nodes in the staging system for medullary thyroid cancer: validating a modified American Joint Committee on cancer tumor-node-metastasis staging system. Thyroid 2022 32 536\u2013543. (https:\/\/doi.org\/10.1089\/thy.2021.0571)"},{"key":"bib30","series-title":"Thorac Cancer","article-title":"Suitability of frozen pleural fluid pellets for next-generation sequencing-based driver gene testing in non-small cell lung cancer","volume":"16","author":"Nakashima K","year":"2025","unstructured":"Nakashima K\n, \nOtsubo K\n, \nTsuchiya-Kawano Y\n, et al.\n Suitability of frozen pleural fluid pellets for next-generation sequencing-based driver gene testing in non-small cell lung cancer. Thorac Cancer 2025 16 e70107. (https:\/\/doi.org\/10.1111\/1759-7714.70107)"},{"key":"bib31","series-title":"Curr Oncol","first-page":"e595","article-title":"Reconsidering the turnaround times for BRAF V600 mutation analysis in non-small-cell lung cancer: a molecular diagnosis in one day is achievable for rapid treatment choices","volume":"26","author":"Uguen A","year":"2019","unstructured":"Uguen A\n\n. Reconsidering the turnaround times for BRAF V600 mutation analysis in non-small-cell lung cancer: a molecular diagnosis in one day is achievable for rapid treatment choices. Curr Oncol 2019 26 e595\u2013e596. (https:\/\/doi.org\/10.3747\/co.26.4779)"},{"key":"bib32","series-title":"Eur J Cancer","first-page":"210","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama T","year":"2022","unstructured":"Higashiyama T\n, \nSugino K\n, \nHara H\n, et al.\n Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer 2022 173 210\u2013218. (https:\/\/doi.org\/10.1016\/j.ejca.2022.06.044)"},{"key":"bib33","series-title":"Thyroid","first-page":"1076","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks C","year":"2021","unstructured":"Dierks C\n, \nSeufert J\n, \nAumann K\n, et al.\n Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 2021 31 1076\u20131085. (https:\/\/doi.org\/10.1089\/thy.2020.0322)"},{"key":"bib34","series-title":"Clin Cancer Res","first-page":"3757","article-title":"Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers","volume":"30","author":"French JD","year":"2024","unstructured":"French JD\n, \nHaugen BR\n, \nWorden FP\n, et al.\n Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. Clin Cancer Res 2024 30 3757\u20133767. (https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-3417)"},{"key":"bib35","series-title":"Curr Oncol","first-page":"5401","article-title":"Combination of lenvatinib and pembrolizumab as salvage treatment for paucicellular variant of anaplastic thyroid cancer: a case report","volume":"28","author":"Luongo C","year":"2021","unstructured":"Luongo C\n, \nPorcelli T\n, \nSessa F\n, et al.\n Combination of lenvatinib and pembrolizumab as salvage treatment for paucicellular variant of anaplastic thyroid cancer: a case report. Curr Oncol 2021 28 5401\u20135407. (https:\/\/doi.org\/10.3390\/curroncol28060450)"},{"key":"bib36","series-title":"BMC Endocr Disord","first-page":"25","article-title":"First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study","volume":"24","author":"Soll D","year":"2024","unstructured":"Soll D\n, \nBischoff P\n, \nFrisch A\n, et al.\n First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. BMC Endocr Disord 2024 24 25. (https:\/\/doi.org\/10.1186\/s12902-024-01555-y)"},{"key":"bib37","series-title":"Endocr J","first-page":"545","article-title":"The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery","volume":"72","author":"Sugitani I","year":"2025","unstructured":"Sugitani I\n, \nKiyota N\n, \nIto Y\n, et al.\n The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery. Endocr J 2025 72 545\u2013635. (https:\/\/doi.org\/10.1507\/endocrj.ej24-0644)"},{"key":"bib38","series-title":"J Natl Cancer Inst","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse P","year":"2000","unstructured":"Therasse P\n, \nArbuck SG\n, \nEisenhauer EA\n, et al.\n New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 205\u2013216. (https:\/\/doi.org\/10.1093\/jnci\/92.3.205)"},{"key":"bib39","series-title":"Thyroid","first-page":"918","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins DP","year":"2014","unstructured":"Blevins DP\n, \nDadu R\n, \nHu M\n, et al.\n Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 2014 24 918\u2013922. (https:\/\/doi.org\/10.1089\/thy.2012.0598)"},{"key":"bib40","series-title":"Eur Thyroid J","first-page":"399","article-title":"Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer","volume":"10","author":"Valerio L","year":"2021","unstructured":"Valerio L\n, \nGiani C\n, \nAgate L\n, et al.\n Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer. Eur Thyroid J 2021 10 399\u2013407. (https:\/\/doi.org\/10.1159\/000514182)"},{"key":"bib41","series-title":"N Engl J Med","first-page":"621","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger M","year":"2015","unstructured":"Schlumberger M\n, \nTahara M\n, \nWirth LJ\n, et al.\n Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015 372 621\u2013630. (https:\/\/doi.org\/10.1056\/nejmoa1406470)"},{"key":"bib42","series-title":"J Clin Oncol","first-page":"2359","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth LJ","year":"2021","unstructured":"Wirth LJ\n, \nBrose MS\n, \nSherman EJ\n, et al.\n Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol 2021 39 2359\u20132366. (https:\/\/doi.org\/10.1200\/jco.20.03093)"},{"key":"bib43","series-title":"Oncol Lett","first-page":"416","article-title":"Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer","volume":"26","author":"Iwasaki H","year":"2023","unstructured":"Iwasaki H\n, \nToda S\n, \nTakahashi A\n, et al.\n Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer. Oncol Lett 2023 26 416. (https:\/\/doi.org\/10.3892\/ol.2023.14002)"},{"key":"bib44","series-title":"Endocrine","first-page":"208","article-title":"Lenvatinib for unresectable anaplastic thyroid cancer: real-world experiences in multi-institutional study","volume":"90","author":"Mikoshiba T","year":"2025","unstructured":"Mikoshiba T\n, \nSekimizu M\n, \nKono T\n, et al.\n Lenvatinib for unresectable anaplastic thyroid cancer: real-world experiences in multi-institutional study. Endocrine 2025 90 208\u2013214. (https:\/\/doi.org\/10.1007\/s12020-025-04333-5)"},{"key":"bib45","series-title":"J Clin Endocrinol Metab","first-page":"4103","article-title":"Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer","volume":"101","author":"Robinson B","year":"2016","unstructured":"Robinson B\n, \nSchlumberger M\n, \nWirth LJ\n, et al.\n Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 2016 101 4103\u20134109. (https:\/\/doi.org\/10.1210\/jc.2015-3989)"},{"key":"bib46","series-title":"Anticancer Res","first-page":"3871","article-title":"Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer","volume":"39","author":"Staub Y","year":"2019","unstructured":"Staub Y\n, \nNishiyama A\n, \nSuga Y\n, et al.\n Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer. Anticancer Res 2019 39 3871\u20133878. (https:\/\/doi.org\/10.21873\/anticanres.13537)"},{"key":"bib47","series-title":"Cancer Chemother Pharmacol","first-page":"971","article-title":"Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer","volume":"82","author":"Hayato S","year":"2018","unstructured":"Hayato S\n, \nShumaker R\n, \nFerry J\n, et al.\n Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer Chemother Pharmacol 2018 82 971\u2013978. (https:\/\/doi.org\/10.1007\/s00280-018-3687-4)"},{"key":"bib48","series-title":"Front Oncol","article-title":"Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study","volume":"13","author":"Matsuyama C","year":"2023","unstructured":"Matsuyama C\n, \nEnokida T\n, \nUeda Y\n, et al.\n Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 2023 13 1139659. (https:\/\/doi.org\/10.3389\/fonc.2023.1139659)"},{"key":"bib49","series-title":"Thyroid","first-page":"566","article-title":"A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer","volume":"34","author":"Tahara M","year":"2024","unstructured":"Tahara M\n, \nTakami H\n, \nIto Y\n, et al.\n A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid 2024 34 566\u2013574. (https:\/\/doi.org\/10.1089\/thy.2023.0553)"},{"key":"bib50","series-title":"Front Oncol","article-title":"Core needle biopsy can early and precisely identify large thyroid masses","volume":"12","author":"Matrone A","year":"2022","unstructured":"Matrone A\n, \nDe Napoli L\n, \nTorregrossa L\n, et al.\n Core needle biopsy can early and precisely identify large thyroid masses. Front Oncol 2022 12 854755. (https:\/\/doi.org\/10.3389\/fonc.2022.854755)"},{"key":"bib51","series-title":"Front Endocrinol","article-title":"Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: a systematic review and meta-analysis","volume":"13","author":"Vander Poorten V","year":"2022","unstructured":"Vander Poorten V\n, \nGoedseels N\n, \nTriantafyllou A\n, et al.\n Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: a systematic review and meta-analysis. Front Endocrinol 2022 13 971249. (https:\/\/doi.org\/10.3389\/fendo.2022.971249)"},{"key":"bib52","series-title":"Int J Clin Oncol","first-page":"1143","article-title":"Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer","volume":"30","author":"Onaga R","year":"2025","unstructured":"Onaga R\n, \nEnokida T\n, \nSakashita S\n, et al.\n Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer. Int J Clin Oncol 2025 30 1143\u20131151. (https:\/\/doi.org\/10.1007\/s10147-025-02760-y)"},{"key":"bib53","series-title":"Acta Neuropathol","first-page":"11","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper D","year":"2011","unstructured":"Capper D\n, \nPreusser M\n, \nHabel A\n, et al.\n Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011 122 11\u201319. (https:\/\/doi.org\/10.1007\/s00401-011-0841-z)"},{"key":"bib54","series-title":"Ann Oncol","first-page":"742","article-title":"Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients","volume":"24","author":"Ilie M","year":"2013","unstructured":"Ilie M\n, \nLong E\n, \nHofman V\n, et al.\n Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013 24 742\u2013748. (https:\/\/doi.org\/10.1093\/annonc\/mds534)"},{"key":"bib55","series-title":"Head Neck Pathol","first-page":"1067","article-title":"Comparison of molecular methods and BRAF immunohistochemistry (VE1 clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis","volume":"14","author":"Parker KG","year":"2020","unstructured":"Parker KG\n, \nWhite MG\n & \nCipriani NA\n\n. Comparison of molecular methods and BRAF immunohistochemistry (VE1 clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis. Head Neck Pathol 2020 14 1067\u20131079. (https:\/\/doi.org\/10.1007\/s12105-020-01166-8)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/5\/ETJ-25-0212.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/5\/ETJ-25-0212.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/5\/ETJ-25-0212.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:32:54Z","timestamp":1766575974000},"score":1,"resource":{"primary":{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/5\/ETJ-25-0212.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":110,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0212","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}